Detailed Narrative
BRUKINSA Global Leadership
BRUKINSA achieved a significant milestone, surpassing $1 billion in quarterly global revenue for the first time and becoming the global value share leader among BTK inhibitors. This success is attributed to a decade of accumulating evidence from preclinical studies, head-to-head trials, real-world data, and patient/physician preference, demonstrating its efficacy and safety profile, particularly in long-term CLL outcomes. The 6-year PFS data in first-line CLL from the SEQUOIA trial showed 74%, which is double-digit better than other single-agent BTKis at 72 months.
Sonro Pipeline Advancement
Sonro, the next-generation BCL2 inhibitor, received FDA breakthrough therapy designation for relapsed/refractory mantle cell lymphoma. The company is actively pursuing global filings for approval, with accelerated approval anticipated in China early next year. Early data for Sonro monotherapy in relapsed/refractory MCL showed an overall response rate of 53% and median PFS of 6.5 months, while in CLL, it achieved a 76% ORR with 19% complete responses, both looking favorable compared to historical data.
ZS Fixed Duration Regimen
The combination of zanu (BRUKINSA) and sonro (ZS) is being developed as a potentially best-in-class fixed duration regimen for CLL. Clinical data shows high rates of deep response, with a median time to uMRD of only 4 months, significantly faster than other combinations like AV (10-16 months). A Phase III trial comparing ZS to VO in relapsed/refractory CLL has completed enrollment, and another global Phase III study comparing ZS to AV in treatment-naive CLL is planned for H1 2026 to formally establish ZS as the best oral fixed duration regimen.
BTK CDAC Progress
The BTK CDAC (BGB-16673) is positioned as a best-in-class BTK degrader, with a head-to-head Phase III trial against pirtobrutinib initiated for relapsed/refractory CLL. A pivotal Phase II study in relapsed/refractory CLL is expected to read out in H1 2026. Data presented at ASH demonstrated an 86.4% ORR and 79% 12-month PFS in CLL, with broad mutation coverage that includes all BTK mutants except A42AD, reinforcing its potential across multiple B-cell malignancies.
Solid Tumor Pipeline Momentum
BeOne's solid tumor pipeline is maturing rapidly, with proof-of-concept achieved for several innovative programs, including the CDK4 inhibitor, B7-H4 ADC, PRMT5 inhibitor, and GPC3x4-1BB bispecifics. The CDK4 inhibitor is slated for a Phase III trial in first-line hormone receptor positive breast cancer in H1 2026, driven by strong emerging efficacy and safety data. The PRMT5 inhibitor is being accelerated into frontline lung and pancreatic cancer due to its high potency, CNS penetration, and favorable safety profile.
R&D Efficiency and Strategy
The company highlighted its 'development global super highway,' a vertically integrated clinical development and manufacturing organization of nearly 6,000 colleagues. This structure enables rapid program advancement, with 16 new molecular entities entering the clinic in the past few years, and programs completing R&D-enabling studies in a median of 10 months. Strategic decisions were made to realign B7-H3 ADC and Pro-IL15 programs to focus resources on differentiated assets with clear clinical proof-of-concept.